

Belsomra[®], Dayvigo[®], QuviviqTM Prior Authorization Request Form DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#: Specialty:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
Check if requesting brand			Directions for Use:		
Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
Insomnia					
Other diagnosis:			ICD-10 Code(s):		
Medication histo	•				
Has the patient had a trial (at least a 14 day trial in the last 180 days) and inadequate response, adverse					
reaction (prescriber must have documented it on a MedWatch form), or contraindication to generic immediate release oral zolpidem tablets or brand Ambien tablets? ☐ Yes ☐ No					
Quantity limit requests:					
What is the quantity requested per DAY?					
What is the reason for exceeding the plan limitations?					
Titration or loading dose purposes					
Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at hadtime)					
tablets at bedtime) Requested strength/dose is not commercially available 					
Other:					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					

Please note:

This request may be denied unless all required information is received. For urgent or expedited requests please call 1-855-401-4262. This form may be used for non-urgent requests and faxed to 1-844-403-1029.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information

in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Belsomra_Dayvigo_Quviviq_SouthDakotaMedicaid_2022October